Landscape Capital Management L.L.C. Makes New $2.08 Million Investment in CeriBell, Inc. $CBLL

Landscape Capital Management L.L.C. purchased a new position in shares of CeriBell, Inc. (NASDAQ:CBLL) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 106,819 shares of the company’s stock, valued at approximately $2,078,000. Landscape Capital Management L.L.C. owned 0.28% of CeriBell as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CBLL. BlackRock Inc. purchased a new stake in shares of CeriBell in the 2nd quarter valued at $37,657,000. Deutsche Bank AG purchased a new position in CeriBell during the 2nd quarter valued at about $1,742,000. TimesSquare Capital Management LLC purchased a new position in CeriBell during the 2nd quarter valued at about $15,182,000. Bank of New York Mellon Corp acquired a new position in CeriBell in the 2nd quarter valued at about $17,437,000. Finally, Kopp Family Office LLC purchased a new stake in CeriBell during the second quarter worth about $672,000.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

Analyst Ratings Changes

Several brokerages have recently issued reports on CBLL. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday. BTIG Research upped their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group increased their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and an average target price of $22.40.

Insider Buying and Selling at CeriBell

In other CeriBell news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the sale, the insider owned 3,765,054 shares of the company’s stock, valued at approximately $75,752,886.48. This trade represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Xingjuan Chao sold 31,415 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total transaction of $786,317.45. Following the sale, the chief executive officer owned 787,799 shares of the company’s stock, valued at $19,718,608.97. This represents a 3.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 369,286 shares of company stock worth $7,718,927. 17.70% of the stock is currently owned by corporate insiders.

CeriBell Price Performance

CeriBell stock opened at $24.20 on Friday. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company has a fifty day simple moving average of $19.54 and a 200-day simple moving average of $19.22. The stock has a market cap of $928.80 million, a P/E ratio of -13.75 and a beta of 0.81. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities analysts expect that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.